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Thienopyridine skeleton has been reported as havi ng inte rest-
ing biological activity, namely antitumorlll and antiangiogenic121 
activities. Herein, we describe the synthesis of thienopyridine ar-
ylethers la-f in moderate to good yields by a copper-cata lyzed 
C- 0 coupling, using N,N-dimethylglycine as a ligand, of the 
7-bromothieno[3,2-b]pyridine, also prepared with substituted 
phenols (see scheme). 
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1a, R1=F, R2=R3=H 63% 
1b, R1=R3=H. R2=F 61% 
1c, R1=R2=H, R3=F 66% 
1d, R1=0Me, R2=R3=H 40% 
1e, R1=R3=H, R2=0Me 50% 
1f. R1=R2=H, R3=0Me 45% 
The growth inhibitory activity of the di(hetero)arylethers la-f was 
evaluated against four human tumor ce ll lines (MCF-7, NCI-H460, 
HepG2 and Hela), using the sulforhodamine B assay. Furthermore, 
t he hepatotoxicity of compounds was studied using a porcine liver 
primary ce ll cu lture (PLPl ). The most promising compound was 
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shown to be the methoxy derivative (le) presenting Gl50 values in 
the range of 1.5 to 6.5 J.LM. For this compound, more studies are 
needed to fi nd its mechanism(s) of action. 
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Aldose reductase's (ALR2) involvement on the onset and progression 
of diabetes secondary complications has attracted attention over the 
years. Ill Furthermore, recent evidence point towards ALR2's implica-
tion in inflammatory pathologies.121 As such, ALR2 comprises a compel-
ling target for medicinal chemistry. 
In the plethora of aldose reductase inhibitors (ARis) synthesized 
so far, two categories are the most studied, namely that of cyclic 
imides and carboxylic acid derivatives. However, a number of cyclic 
imide derivatives emerged w ith acute side effects and carboxylic 
acids presented with poor membrane penetration. 
In our previous work and in order to overcome the limitations of 
the two classic ca tegories of ARis, we have presented a successful 
bioisosteric replacement of a carboxylic acid moiety with t hat of a 
2,6-difluorophenof.13·•J 2,6-Difluorophenol has a pK,, va lue of 7. 12, 
therefore its derivatives could diffuse through membranes more ad-
eq uately than their carboxylate counterparts. In the present work, we 
investigated the synthetic feasibility and ARI activity of aroylpyrroles 
bearing groups that are non-anionic in physiological pH such as the 
phenol, 2-fluorophenol, salicylaldoxime, nitroaldoxime, and 3,4-di-
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